ecancermedicalscience

Research

Retrospective analysis of the role of cyclin E1 overexpression as a predictive marker for the efficacy of bevacizumab in platinum-sensitive recurrent ovarian cancer

5 Jul 2021
Adriana Regina Gonçalves Ribeiro, Marcela Marineli Salvadori, Louise de Brot, Graziele Bovolin, Henrique Mantoan, Felipe Ilelis, Mariana Rezende, Nayra Soares do Amaral, Solange Moraes Sanches, Joyce Maria Lisboa Maya, Elizabeth Santana dos Santos, Ronaldo Pereira, Fabrício de Souza Castro, João Paulo da Nogueira Silveira Lima, Andrea Paiva Gadelha Guimarães, Glauco Baiocchi, Alexandre André Balieiro Anastácio da Costa

The relative benefit of bevacizumab in ovarian cancer (OC) patients is greater the more the disease becomes platinum-resistant. Among other mechanisms of action, antiangiogenic agents may induce homologous recombination deficiency. Cyclin E1 (CCNE1) overexpression is a proposed marker of platinum resistance and is mutually exclusive with deficiency in homologous recombination. In this study, we evaluated the predictive value of CCNE1 expression with regard to the efficacy of bevacizumab. We retrospectively evaluated data from patients with platinum-sensitive recurrent OC who were treated with chemotherapy (CT) plus bevacizumab (Bev group) or CT alone (CT group) at a tertiary cancer centre from 2005 to 2017. The two groups were paired according to histology, platinum-free interval (PFI) and number of previous treatment lines. Progression-free survival (PFS) was compared between groups by log rank test and Cox regression. A total of 124 patients were included, with 62 in each group. The groups were well balanced regarding histology, PFI and number of previous treatment lines. Median PFS (mPFS) was 19.5 months for the Bev group versus 16.0 months for CT group (p = 0.150). By multivariate analysis, the HR for PFS was 2.25 (95% CI: 1.10–4.60) for CCNE1 overexpression. The benefit of bevacizumab was larger in the subgroups of patients with PFI 6–12 months (mPFS 18.6 versus 10.4 months, p = 0.002) and CCNE1 overexpression (mPFS 16.3 versus 7.0 months, p = 0.010). In conclusion, CCNE1 overexpression and PFI may suggest which patients will receive the greatest benefit from bevacizumab. These data, if confirmed by other studies, could help better select patients for antiangiogenic therapy.

Related Articles

Renata Colombo Bonadio, Ana Paula Messias, Otavio Augusto Moreira, Letícia Vecchi Leis, Bruna Zanin Orsi, Laura Testa, Maria del Pilar Estevez-Diz
Sandip Ganguly, Sumedha Gargy, Archisman Basu, Meheli Chatterjee, Anik Ghosh, Basumita Chakraborti, Bivas Biswas, Deepak Dabkara, Shweta Rai, Arunava Roy, Sonia Mathai, Jaydip Bhaumik, Joydeep Ghosh
Babita Kataria, Aparna Sharma, Bivas Biswas, Sameer Bakhshi, Deepam Pushpam